Last Updated : June 6, 2019
Details
In 2018, around 270,000 Canadians were living with inflammatory bowel disease (IBD), which comprises Crohn’s disease and ulcerative colitis. Several drug classes, including corticosteroids, immunomodulators and anti-inflammatory biologics, can induce and maintain remission of IBD. Canada's Drug Agency has undertaken a series of reviews of the clinical and economic evidence surrounding drugs for IBD to clarify their relative place in therapy and inform appropriate reimbursement criteria by public drug plans.